文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

同种异体人骨髓间充质干细胞静脉输注治疗特发性肺纤维化(AETHER):Ⅰ期安全性临床试验

Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
PubMed 文献 · Chest · 2016-11-24
一句话结论在轻中度特发性肺纤维化患者中,单次静脉输注人骨髓间充质干细胞(20、100或200×10⁶个)未报告治疗相关严重不良事件,支持其安全性。

AETHER试验是首个评估单次静脉输注骨髓来源间充质干细胞治疗特发性肺纤维化安全性的Ⅰ期研究。9例轻中度IPF患者序贯入组3个剂量组,分别接受20、100或200×10⁶个细胞单次静脉输注。主要终点为输注后4周内治疗相关严重不良事件(死亡、非致命性肺栓塞、卒中、因呼吸困难加重住院、有临床意义的实验室异常)的发生率。结果未报告治疗相关严重不良事件,2例死亡与疾病进展相关;至60周时%预计值FVC平均下降3.0%,%预计值DLCO平均下降5.4%。

要点

  • 9例轻中度IPF患者序贯接受单次静脉输注20、100或200×10⁶个骨髓间充质干细胞,未报告治疗相关严重不良事件。
  • 主要终点为输注后4周内治疗相关严重不良事件复合终点(死亡、非致命性肺栓塞、卒中、因呼吸困难加重住院、有临床意义的实验室异常)。
  • 2例死亡与IPF进展相关(疾病加重和/或急性加重),判定为非治疗相关。
  • 至输注后60周,%预计值FVC平均下降3.0%,%预计值DLCO平均下降5.4%。
  • 安全性随访至60周并额外延长28天,结论支持单次静脉输注间充质干细胞在轻中度IPF中的安全性。

适用人群与场景

  • 轻中度特发性肺纤维化患者,共9例,序贯分配至3个剂量组。
  • 所有基线资料由多学科研究团队审核以确保诊断准确。

处置流程与药物剂量

  • 单次静脉输注人骨髓来源间充质干细胞,剂量分别为20×10⁶、100×10⁶或200×10⁶个/次,细胞来自年轻无关男性供者。

研究设计与关键结果

  • Ⅰ期安全性临床试验,9例轻中度IPF患者序贯入组3个剂量组(20、100、200×10⁶个细胞单次静脉输注),未设对照。
  • 主要终点:输注后4周内治疗相关严重不良事件(死亡、非致命性肺栓塞、卒中、因呼吸困难加重住院、有临床意义的实验室异常复合终点)发生率为0,未报告任何治疗相关严重不良事件。
  • 2例死亡与IPF进展相关(疾病加重和/或急性加重),判定为非治疗相关。
  • 至输注后60周,%预计值FVC平均下降3.0%,%预计值DLCO平均下降5.4%;次要疗效终点为探索性。

证据类型、等级与局限

  • 证据类型:Ⅰ期安全性临床试验(单臂、序贯剂量递增设计)。
  • 原文结论:数据支持单次静脉输注人间充质干细胞在轻中度IPF患者中的安全性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论支持单次静脉输注人骨髓间充质干细胞在轻中度IPF患者中的安全性,但本研究为Ⅰ期小样本单臂试验,未评估疗效。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Despite Food and Drug Administration approval of 2 new drugs for idiopathic pulmonary fibrosis (IPF), curative therapies remain elusive and mortality remains high. Preclinical and clinical data support the safety of human mesenchymal stem cells as a potential novel therapy for this fatal condition. The Allogeneic Human Cells (hMSC) in patients with Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER) trial was the first study designed to evaluate the safety of a single infusion of bone marrow-derived mesenchymal stem cells in patients with idiopathic pulmonary fibrosis.

METHODS: Nine patients with mild to moderate IPF were sequentially assigned to 1 of 3 cohorts and dosed with a single IV infusion of 20, 100, or 200 × 106 human bone marrow-derived mesenchymal stem cells per infusion from young, unrelated, men. All baseline patient data were reviewed by a multidisciplinary study team to ensure accurate diagnosis. The primary end point was the incidence (at week 4 postinfusion) of treatment-emergent serious adverse events, defined as the composite of death, nonfatal pulmonary embolism, stroke, hospitalization for worsening dyspnea, and clinically significant laboratory test abnormalities. Safety was assessed until week 60 and additionally 28 days thereafter. Secondary efficacy end points were exploratory and measured disease progression.

RESULTS: No treatment-emergent serious adverse events were reported. Two nontreatment-related deaths occurred because of progression of IPF (disease worsening and/or acute exacerbation). By 60 weeks postinfusion, there was a 3.0% mean decline in % predicted FVC and 5.4% mean decline in % predicted diffusing capacity of the lungs for carbon monoxide.

CONCLUSIONS: Data from this trial support the safety of a single infusion of human mesenchymal stem cells in patients with mild-moderate IPF.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02013700; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial. Chest. 2016. PMID: 27890713. doi:10.1016/j.chest.2016.10.061

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。